This NACI guidance offers a preliminary framework to advise Canadian provinces and territories (PTs) on whether to use human vaccines against avian influenza (HVAI) in a non-pandemic context, centered on the objective to prevent human infection with avian influenza A(H5N1) viruses. Preventing transmission from animals to humans will help to prevent severe disease in humans and could also help limit opportunities for viral adaptations that could facilitate human-to-human transmission.
In the event that PTs determine it is necessary to start offering HVAI, NACI has identified key populations to consider prioritizing for vaccination including laboratory workers handling live avian influenza A (H5N1) virus and people with ongoing contact with known infected animals or their environments. NACI has also provided product-specific advice to advise PTs on recommended use of HVAI should it be needed (e.g., recommended schedule, guidance on concurrent administration).